Search filters

Filters
Clear All

Phase

  • 1
  • 1
  • 2
  • 1
  • 5
  • 2
  • 5

Found 5 Pulmonary Arterial Hypertension trials

A listing of Pulmonary Arterial Hypertension medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 A Randomized Study to Compare Efficacy  Safety  and Tolerability of Macitentan 75mg Versus Macitentan 10mg in Patients with Pulmonary Arterial Hypertension  Followed by an Open-label Treatment Period with Macitentan 75mg
18 years - 75 years
All genders
Phase 3
TThe research study is being conducted to compare macitentan 75 mg with the approved macitentan 10 mg to see if it is well tolerated, safe and useful for treating patients with pulmonary arterial hypertension (PAH).
99 years or below
All genders
Phase 1
This Phase 1b, open-label, multicenter study will be conducted to evaluate the safety and tolerability of treprostinil inhalation powder (TreT) in subjects with PAH currently ssing Tyvaso. A minimum of 45 patients from 15 sites in the US will be enrolled in the study.
 A Clinical Study to Evaluate the Efficacy and Safety of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)
18 years - 75 years
All genders
Phase 2
Interventional
The objective for this trial is to determine the effect of GB002 (seralutinib) on improving pulmonary hemodynamics in subjects with World Health Organization (WHO) Group 1 PAH who are Functional Class (FC) II and III.
 A Randomized, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects with Pulmonary Arterial Hypertension, “Ambition” Trial
18 years - 75 years
All genders
Phase 3
Interventional
This clinical research study involves an experimental combination of two drugs, ambrisentan and tadalafil for the treatment of Pulmonary Arterial Hypertension (a narrowing of the arteries connecting the lungs to the heart that leads to an increase in blood pressure). This is also known as PAH. These drugs have been …
99 years or below
All genders
Phase 4
This is a prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group, exploratory Phase 4 study. The purpose is to identify the effect of selexipag on daily life physical activity assessed by a wearable device in patients with PAH (WHO Group 1). Approximately 100 patients will be enrolled in the study at 45 …